Byondis to Present Data from its Novel ADC Technology Platforms at the American Society for Cancer Research Meeting 2026

NIJMEGEN, The Netherlands--(BUSINESS WIRE)--Byondis B.V., an independent biopharmaceutical company creating innovative targeted medicines for patients with cancer, will profile the Company’s first-in-class antifolate and phosphonate antibody-drug conjugate (ADC) technology platforms in poster sessions at the American Society for Cancer Research (AACR) Annual Meeting 2026 in San Diego, CA, from today through to 22 April. Wim Dokter, PhD, Chief Scientific Officer at Byondis, said: “The research w
2026-04-17 11:00:00